Anti-GLIS3 Rabbit Polyclonal Antibody for WB and ELISA - Q8NEA6

Core Product Specifications and Parameters

Biological Background: GLIS3 Function and Localization

• Zinc finger protein GLIS3, also known as GLI-similar 3 or ZNF515, is a transcription factor from the GLI family of zinc finger proteins.
• Functioning as both a transcriptional repressor and activator, GLIS3 binds to the consensus DNA sequence 5'-GACCACCCAC-3' (by similarity).
• GLIS3 localizes predominantly to the nucleus, consistent with its role in transcriptional regulation.
• It is highly expressed in kidney, with lower levels detected in brain, skeletal muscle, pancreas, liver, lung, thymus, and ovary.
• GLIS3 contains multiple zinc finger domains that mediate DNA binding and metal coordination.
• The gene is associated with congenital hypothyroidism and diabetes mellitus, underscoring its importance in endocrine development and function.
• Alternative splicing generates multiple isoforms, expanding the functional diversity of GLIS3.

Experimental Guidance and Technical Tips

• For Western blotting, validate the expected band at ~84 kDa and consider using extracts from kidney tissue, where GLIS3 is highly expressed, to confirm specificity.
• When performing ELISA, optimize coating antigen concentration and antibody dilution using a known GLIS3-positive control.
• Due to the polyclonal nature of this antibody, slight lot-to-lot variation may occur; include appropriate positive and negative controls in each experiment.
• Cross-reactivity with mouse and rat GLIS3 allows for testing in rodent models, but verify sequence homology in the immunogen region for consistent results.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research institutes with convenient access to high-quality IVD raw materials. This anti-GLIS3 polyclonal antibody supports research into transcription regulation, diabetes, and hypothyroidism. In addition to this product, CamelBio supplies validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and sourcing services for rare targets, helping you move from concept to clinic efficiently.